Synlogic Achieves Milestone in Development of Synthetic Biotic for IBD

Synlogic, Inc (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced on 3/6/19 the advancement of Synthetic Biotic medicines to the lead optimization stage in its collaboration with AbbVie, a global biopharmaceutical company, to develop an oral treatment for inflammatory bowel disease (IBD).